Globus Medical Inc GMED
We take great care to ensure that the data presented and summarized in this overview for GLOBUS MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMED
View all-
Vanguard Group Inc Valley Forge, PA10.6MShares$896 Million0.01% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$873 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.55MShares$638 Million0.21% of portfolio
-
Jpmorgan Chase & CO New York, NY3.68MShares$311 Million0.01% of portfolio
-
Sculptor Capital LP New York, NY3.5MShares$296 Million5.4% of portfolio
-
State Street Corp Boston, MA3.46MShares$292 Million0.01% of portfolio
-
Burgundy Asset Management Ltd. Toronto, A63.46MShares$292 Million1.96% of portfolio
-
William Blair Investment Management, LLC Chicago, IL2.82MShares$238 Million0.45% of portfolio
-
Madison Avenue Partners, LP New York, NY2.55MShares$215 Million13.35% of portfolio
-
Geneva Capital Management LLC2.08MShares$176 Million2.07% of portfolio
Latest Institutional Activity in GMED
Top Purchases
Top Sells
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Insider Transactions at GMED
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2025
|
David C Paul Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
34,375
+36.26%
|
$859,375
$25.52 P/Share
|
|
Dec 01
2025
|
Kyle Kline Senior Vice President, CFO |
SELL
Open market or private sale
|
Direct |
18,542
-100.0%
|
$1,668,780
$90.0 P/Share
|
|
Dec 01
2025
|
Kyle Kline Senior Vice President, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,542
+33.59%
|
$1,093,978
$59.42 P/Share
|
|
Nov 25
2025
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$675,000
$90.0 P/Share
|
|
Nov 25
2025
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$187,500
$25.96 P/Share
|
|
Nov 12
2025
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
25,000
-4.62%
|
$2,150,000
$86.0 P/Share
|
|
Nov 12
2025
|
David D Davidar |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.41%
|
$625,000
$25.52 P/Share
|
|
Nov 11
2025
|
Stephen T Zarrilli |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$2,100,000
$84.29 P/Share
|
|
Nov 11
2025
|
Stephen T Zarrilli |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$1,100,000
$44.14 P/Share
|
|
Nov 10
2025
|
Ann D Rhoads |
SELL
Open market or private sale
|
Direct |
2,000
-11.5%
|
$170,000
$85.0 P/Share
|
|
Nov 07
2025
|
Ann D Rhoads |
SELL
Open market or private sale
|
Direct |
8,000
-31.52%
|
$648,000
$81.0 P/Share
|
|
Sep 15
2025
|
Ann D Rhoads |
SELL
Open market or private sale
|
Direct |
10,000
-28.26%
|
$580,000
$58.46 P/Share
|
|
Feb 28
2025
|
Ann D Rhoads |
SELL
Open market or private sale
|
Direct |
7,500
-17.49%
|
$585,000
$78.68 P/Share
|
|
Jan 10
2025
|
Keith W Pfeil President, CEO |
SELL
Open market or private sale
|
Direct |
14,167
-94.12%
|
$1,246,696
$88.67 P/Share
|
|
Jan 10
2025
|
Keith W Pfeil President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,167
+43.52%
|
$722,517
$51.46 P/Share
|
|
Dec 02
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$217,500
$87.0 P/Share
|
|
Dec 02
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$60,000
$24.21 P/Share
|
|
Nov 22
2024
|
David D Davidar |
SELL
Open market or private sale
|
Indirect |
6,746
-3.91%
|
$573,410
$85.0 P/Share
|
|
Nov 22
2024
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
6,766
-1.29%
|
$575,110
$85.0 P/Share
|
|
Nov 22
2024
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
1,097
-100.0%
|
$93,245
$85.02 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 125K shares |
|---|
| Open market or private sale | 118K shares |
|---|